bluebird bio, Inc.
NASDAQ:BLUE
4.97 (USD) • At close June 2, 2025
 Overzicht | Financiële gegevens
 | Bedrijfsnaam | bluebird bio, Inc. | 
| Symbool | BLUE | 
| Munteenheid | USD | 
| Prijs | 4.97 | 
| Beurswaarde    |  48,668,526 | 
| Dividendpercentage    |  0% | 
| 52-weken bereik | 3.2 - 28.6 | 
| Industrie | Biotechnology | 
| Sector | Healthcare | 
| CEO | Mr. Andrew Obenshain | 
| Website | https://www.bluebirdbio.com | 
An error occurred while fetching data.
Over bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. 
 Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)









